Two More Sites Added to Spectral AI’s U.S. Burn Study

The University of California-San Diego and the University of Utah are the newest clinical trial sites for Spectral AI Inc.’s 2024 burn study. The two new locations expand the total number of U.S. clinical trial sites to 14.  
 
“These two new sites allow us to capture additional burn patients who enter through the Emergency Department and thus complement our existing trial site presence at burn centers across the country, establish our presence in new geographies, and advance us towards our objective of completing this study by the end of the year,” Spectral AI CEO Peter M. Carlson said. “Moreover, a broader base of clinical trial sites provides access to a more diverse patient population, reduces bias, and provides the opportunity to elevate the profile of our DeepView™ System across a wider range of clinicians and healthcare settings.”   
 
The 2024 U.S. Burn pivotal study is designed to validate the AI-driven algorithm used by Spectral AI’s DeepView System for burn indication. The study is scheduled to be completed in the fourth quarter this year and expected to be the final clinical trial before the company seeks U.S. Food and Drug Administration approval of its DeepView System for burn indication in 2025.
 
Spectral AI Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The company is working to significantly improve wound care management by “Seeing the Unknown” with its DeepView System. The DeepView System is a predictive device that offers clinicians an objective and immediate assessment of a wound’s healing potential before treatment or other medical intervention. With algorithm-driven results and a goal to change the current standard of care, the DeepView System is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs.